Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulations. With the publication of this announcement, this information is now considered to be in the public domain.

20 December 2021

Proteome Sciences plc
("Proteome Sciences" or the "Company")

Substantial contract win for Proteome Sciences

London, December 20, 2021. Proteome Sciences is pleased to announce that the Company has secured a contract in excess of GBP 1 million from a major pharmaceutical company to analyse large cohorts of clinical samples from a phase 3 clinical trial. Work is expected to start early in the first quarter of 2022 and the majority of revenue is expected to be generated in 2022.

Commenting on the contract, Richard Dennis, Chief Commercial Officer of Proteome Sciences said:

"We are delighted that Proteome Sciences has been selected as the biomarker CRO of choice for these ongoing clinical studies. The contract will take up a significant part of the expanded capacity that we have added to our services activities in 2022 and into 2023. Our proprietary proteomics services using Tandem Mass Tags (TMTpro™) was key to selecting Proteome Sciences as was the intellectual property in our TMTcalibrator™ technique to boost the sensitivity of mass spectrometry in their selected sample types."

- Ends -

For further information:

Proteome Sciences plc

Richard Dennis, Chief Commercial Officer Tel: +44 (0)20 7043 2116
Dr Mariola Soehngen, Chief Executive Officer
Dr Ian Pike, Chief Scientific Officer

Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale/ Jeremy Porter Tel: +44 (0)20 3328 5656

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.